title: Success rate of implantation and mid-term outcomes of the sirolimus-eluting stent.
abstract: BACKGROUND
  The sirolimus-eluting stent (SES) is currently the sole drug-coated stent approved for use in Japan, but there are few reports on its safety and outcomes in Japan.
  
  
  RESULTS
  From May 2004 to February 2005, a total of 297 patients with 402 lesions were treated with SES at 6 hospitals in the Kansai district. Follow-up angiography was performed in 82% of the patients and 80% of the lesions at 182+/-35 days after stenting. Coronary stenosis was evaluated using quantitative coronary angiography. Clinical and angiographic data were analyzed. Minimum lesion diameter was 0.75+/-0.52 mm and the reference diameter was 2.81+/-0.47 mm before stenting. The SES successfully dilated 99.5% of the lesions with few major adverse cardiac events. Restenosis occurred in 4.0% and the target lesion revascularization rate was 3.7%. Restenosis correlated with chronic hemodialysis, calcification, occlusion, ostial lesions, lesions kinked>45 degrees, right coronary artery (RCA) lesions and lesions at the ostium of the RCA.
  
  
  CONCLUSIONS
  SES demonstrated a high rate of successful implantation with few complications, and mid-term outcomes were excellent. Patients with lesions at the ostium of the RCA or under chronic hemodialysis developed restenosis.
authors.affiliation: Third Division, Department of Internal Medicine, Osaka Medical College, Takatsuki, and Department of Cardiology, Kyoto Kujo Hospital, Japan.
authors.forename: Shuji
authors.initials: S
authors.lastname: Suzuki
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kamihata
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Hata
authors.forename: Fujio
authors.initials: F
authors.lastname: Hayashi
authors.forename: Akira
authors.initials: A
authors.lastname: Miura
authors.forename: Masahiro
authors.initials: M
authors.lastname: Yoshinaga
authors.forename: Masahiro
authors.initials: M
authors.lastname: Karakawa
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Kitaura
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000473:pathology / Q000517:prevention & control*; D023921:Coronary Stenosis / Q000473:pathology / Q000628:therapy*; D016503:Drug Delivery Systems; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007564:Japan; D008297:Male; D008875:Middle Aged; D020123:Sirolimus / Q000008:administration & dosage / Q000627:therapeutic use*; D015607:Stents; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D020123:Sirolimus